JP7663508B2 - ジアミノピリミジン化合物を使用することによって、子宮内膜症性疼痛を治療する方法 - Google Patents

ジアミノピリミジン化合物を使用することによって、子宮内膜症性疼痛を治療する方法 Download PDF

Info

Publication number
JP7663508B2
JP7663508B2 JP2021564186A JP2021564186A JP7663508B2 JP 7663508 B2 JP7663508 B2 JP 7663508B2 JP 2021564186 A JP2021564186 A JP 2021564186A JP 2021564186 A JP2021564186 A JP 2021564186A JP 7663508 B2 JP7663508 B2 JP 7663508B2
Authority
JP
Japan
Prior art keywords
days
body weight
compound
pharma
polymorph
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021564186A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022531570A5 (https=
JP2022531570A (ja
JPWO2020221277A5 (https=
Inventor
ヤンピン チャオ，
ファイ ファン，
ホンジュン ワン，
ユアンユアン ジアン，
フイニン リャン，
ラン アン，
チョウ ラン，
ジン ワン，
リイン チョウ，
ヤンアン リウ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Tide Pharmaceutical Co Ltd
Original Assignee
Beijing Tide Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Tide Pharmaceutical Co Ltd filed Critical Beijing Tide Pharmaceutical Co Ltd
Publication of JP2022531570A publication Critical patent/JP2022531570A/ja
Publication of JP2022531570A5 publication Critical patent/JP2022531570A5/ja
Publication of JPWO2020221277A5 publication Critical patent/JPWO2020221277A5/ja
Application granted granted Critical
Publication of JP7663508B2 publication Critical patent/JP7663508B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021564186A 2019-04-30 2020-04-29 ジアミノピリミジン化合物を使用することによって、子宮内膜症性疼痛を治療する方法 Active JP7663508B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/085209 2019-04-30
CN2019085209 2019-04-30
PCT/CN2020/087689 WO2020221277A1 (zh) 2019-04-30 2020-04-29 二氨基嘧啶类化合物治疗子宫内膜异位相关的疼痛的方法

Publications (4)

Publication Number Publication Date
JP2022531570A JP2022531570A (ja) 2022-07-07
JP2022531570A5 JP2022531570A5 (https=) 2023-05-11
JPWO2020221277A5 JPWO2020221277A5 (https=) 2023-05-11
JP7663508B2 true JP7663508B2 (ja) 2025-04-16

Family

ID=73028778

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021564186A Active JP7663508B2 (ja) 2019-04-30 2020-04-29 ジアミノピリミジン化合物を使用することによって、子宮内膜症性疼痛を治療する方法

Country Status (12)

Country Link
US (1) US12605381B2 (https=)
EP (1) EP3960178B1 (https=)
JP (1) JP7663508B2 (https=)
KR (1) KR102935431B1 (https=)
CN (1) CN114007620B (https=)
AU (1) AU2020266947B2 (https=)
BR (1) BR112021021838A8 (https=)
CA (1) CA3138238A1 (https=)
MX (1) MX2021013347A (https=)
SG (1) SG11202111960PA (https=)
TW (1) TWI737285B (https=)
WO (1) WO2020221277A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7207634B2 (ja) 2017-11-01 2023-01-18 ベイジン タイド ファーマシューティカル カンパニー リミテッド Ｐ２ｘ３及び／又はｐ２ｘ２／３受容体アンタゴニスト、それを含む医薬組成物及びその使用
US20250032476A1 (en) * 2021-11-05 2025-01-30 The Regents Of The University Of California Alpha-2a adrenergic receptor modulators and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019508445A (ja) 2016-03-14 2019-03-28 アファレント ファーマシューティカルズ インコーポレイテッド ピリミジンおよびそのバリアント、ならびにそのための使用
JP2019510025A (ja) 2016-03-25 2019-04-11 アファレント ファーマシューティカルズ インコーポレイテッド ピリミジンおよびそのバリアント、ならびにそのための使用
JP2021501184A (ja) 2017-11-01 2021-01-14 ベイジン タイド ファーマシューティカル カンパニー リミテッドＢｅｉｊｉｎｇ Ｔｉｄｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． Ｐ２ｘ３及び／又はｐ２ｘ２／３受容体アンタゴニスト、それを含む医薬組成物及びその使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008104474A1 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag Diaminopyrimidines
USD956213S1 (en) 2020-10-02 2022-06-28 Phillips-Medisize A/S Autoinjector

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019508445A (ja) 2016-03-14 2019-03-28 アファレント ファーマシューティカルズ インコーポレイテッド ピリミジンおよびそのバリアント、ならびにそのための使用
JP2019510025A (ja) 2016-03-25 2019-04-11 アファレント ファーマシューティカルズ インコーポレイテッド ピリミジンおよびそのバリアント、ならびにそのための使用
JP2021501184A (ja) 2017-11-01 2021-01-14 ベイジン タイド ファーマシューティカル カンパニー リミテッドＢｅｉｊｉｎｇ Ｔｉｄｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． Ｐ２ｘ３及び／又はｐ２ｘ２／３受容体アンタゴニスト、それを含む医薬組成物及びその使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EUR. J. MED. CHEM. -CHIMICA THERAPEUTICA，1977年，12(6)，531-536
PLOS ONE，2017年，12(9)，e0184647

Also Published As

Publication number Publication date
BR112021021838A8 (pt) 2023-02-28
BR112021021838A2 (pt) 2022-01-04
KR20220008286A (ko) 2022-01-20
CN114007620B (zh) 2024-08-06
SG11202111960PA (en) 2021-12-30
CA3138238A1 (en) 2020-11-05
EP3960178A1 (en) 2022-03-02
JP2022531570A (ja) 2022-07-07
US20220249478A1 (en) 2022-08-11
MX2021013347A (es) 2022-01-24
TW202106303A (zh) 2021-02-16
KR102935431B1 (ko) 2026-03-05
CN114007620A (zh) 2022-02-01
WO2020221277A1 (zh) 2020-11-05
EP3960178B1 (en) 2026-03-18
US12605381B2 (en) 2026-04-21
TWI737285B (zh) 2021-08-21
AU2020266947A1 (en) 2021-12-16
EP3960178A4 (en) 2023-01-25
AU2020266947B2 (en) 2025-10-09

Similar Documents

Publication Publication Date Title
TWI804743B (zh) 治療特發性肺纖維化的方法
KR102906316B1 (ko) 지방간 질환 및/또는 지방간염의 치료 방법
JP7663508B2 (ja) ジアミノピリミジン化合物を使用することによって、子宮内膜症性疼痛を治療する方法
EP1662875A2 (en) Chelerythrine, analogs thereof and their use in the treatment of bipolar disorder and other cognitive disorders
JP7665529B2 (ja) ジアミノピリミジン化合物を使用することによって咳を治療する方法
JP7803924B2 (ja) 造血幹細胞移植によって引き起こされる移植片対宿主病を治療する方法
HK40062123A (en) Method for treating endometriosis-associated pain by using diaminopyrimidine compound
HK40063619B (zh) 二氨基嘧啶类化合物治疗子宫内膜异位相关的疼痛的方法
HK40063619A (en) Method for treating endometriosis-associated pain by using diaminopyrimidine compound
HK40062124A (en) Method for treating cough by using diaminopyrimidine compound
HK40058942A (en) Method for treating fatty liver disease and/or steatohepatitis

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20211213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240807

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250307

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250401

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250404

R150 Certificate of patent or registration of utility model

Ref document number: 7663508

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150